Đăng xuất
Contraception
Adult: 150 mg given during the 1st 5 days of normal menstrual cycle or within the 1st 5 days following childbirth (delay until 6 weeks after childbirth if breastfeeding). Further doses must be given at 12- or 13-week intervals. Initial administration schedule may vary when switching from another method of contraception to ensure continuous contraceptive coverage (refer to detailed product guideline).
Intramuscular
Hormone-dependent recurrent breast cancer in postmenopausal women
Adult: Initially, 500 mg daily for 4 weeks. Maintenance: 500 mg twice weekly according to patient response.
Intramuscular
Endometrial carcinoma, Renal cell carcinoma
Adult: As adjunctive and/or palliative therapy in advanced inoperable cases including those with metastatic and/or recurrent disease: Initially, 400-1,000 mg weekly. If there is improvement within a few weeks or months and the disease is stabilised, may maintain dose at the lowest recommended dose every month. Dosing recommendations may vary among countries and individual products (refer to specific product guideline).
Intramuscular
Endometriosis
Adult: 50 mg weekly or 100 mg every 2 weeks for at least 6 months.
Oral
Endometrial carcinoma, Renal cell carcinoma
Adult: 200-600 mg daily.
Oral
Endometriosis
Adult: In mild to moderate cases: 10 mg tid for 90 consecutive days, started on the 1st day of menstrual cycle.
Oral
Prophylaxis of endometrial hyperplasia
Adult: In non-hysterectomised postmenopausal women receiving oral conjugated estrogens: 5 or 10 mg daily for 12-14 consecutive days each month, started on the 1st or 16th day of the cycle. Use for the shortest duration possible at the lowest effective dose consistent with the treatment goals. Re-evaluate patients periodically as clinically appropriate.
Oral
Secondary amenorrhoea
Adult: 2.5-10 mg daily for 5-10 days, initiated on the assumed or calculated 16th-21st day of the cycle. Alternatively, treatment may be started at any time. Repeat for 3 consecutive cycles. In cases associated with a poorly developed proliferative endometrium: 5-10 mg for 10 days in conjunction with conventional estrogen therapy.
Oral
Dysfunctional uterine bleeding
Adult: 2.5-10 mg daily for 5-10 days, initiated on the assumed or calculated 16th-21st day of the cycle. Given for 2 consecutive cycles. In case of bleeding from a poorly developed proliferative endometrium: 5-10 mg for 10 days in conjunction with conventional estrogen therapy.
Oral
Breast carcinoma
Adult: In postmenopausal women: 400-1,500 mg daily.
Subcutaneous
Endometriosis
Adult: In cases when other options are considered inadequate: 104 mg every 12-14 weeks.
Subcutaneous
Contraception
Adult: 104 mg during the 1st 5 days of normal menstrual cycle or within the 1st 5 days following childbirth (delay until 6 weeks after childbirth if breastfeeding). Further doses must be given at 12-14 week intervals. Initial administration schedule may vary when switching from another method of contraception to ensure continuous contraceptive coverage (refer to detailed product guideline).
